Greyrock has exited its investment in Alaven Pharmaceutical LLC. Alaven, which provides both prescription and OTC products primary for gastroenterology and women’s health markets, was sold to Meda, AB, a Swedish pharmaceutical company, in a transaction that valued the company at $350 million. Greyrock partnered with DFW Capital Partners in 2006 to provide mezzanine debt and preferred equity to support Alaven’s product acquisition, in-licensing and development strategies.
Greyrock, along with co-investor South Franklin Street Partners, backs the acquisition of DecisionQuest, Inc. by an ESOP providing $12.5 million in subordinated debt. DecisionQuest specializes in customized trial consulting, strategic graphics, presentation technology services and social media analysis.